Clinical Features and Treatment of Scleroderma

Kelley's Textbook of Rheumatology: Volume 1-2, Ninth Edition

Volumn 2, Issue , 2012, Pages 1366-1403

  Boin, Francesco ^a   Wigley, Fredrick M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85167760366     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-1738-9.00084-0     Document Type: Chapter

References (301)

1. GP Rodnan and TG Benedek (1962) An historical account of the study of progressive systemic sclerosis (diffuse scleroderma). Ann Intern Med 57 305-319
2. EE Velayos, AT Masi, MB Stevens, et al. (1979) The ‘CREST’ syndrome: comparison with systemic sclerosis (scleroderma). Arch Intern Med 139 1240-1244
3. WA D’Angelo, JF Fries, AT Masi, et al. (1969) Pathologic observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 46 428-440
4. GP Rodnan, E Lipinski and J Luksick (1979) Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 22 130-140
5. MD Mayes, JVJ Lacey, J Beebe-Dimmer, et al. (2003) Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48 2246-2255
6. FC Arnett, RF Howard, F Tan, et al. (1996) Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma: association with an Amerindian HLA haplotype. Arthritis Rheum 39 1362-1370
7. VD Steen, CV Oddis, CG Conte, et al. (1997) Incidence of systemic sclerosis in Allegheny County, Pennsylvania: a twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum 40 441-445
8. AJ Tyndall, B Bannert, M Vonk, et al. (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69 1809-1815
9. VD Steen and TA Medsger Jr (2000) Long-term outcomes of scleroderma renal crisis. Ann Intern Med 133 600-603
10. VD Steen and TA Medsger (2007) Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66 940-954
11. SI Nihtyanova, EC Tang, JG Coghlan, et al. (2010) Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. Q J Med 103 109-115
12. FC Arnett, M Cho, S Chatterjee, et al. (2001) Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 44 1359-1362
13. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23 581-590
14. CG Kallenberg, AA Wouda, MH Hoet, et al. (1988) Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 47 634-641
15. EC LeRoy and TA Medsger Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28 1573-1576
16. AJ Barnett, M Miller and GO Littlejohn (1988) The diagnosis and classification of scleroderma (systemic sclerosis). Postgrad Med J 64 121-125
17. PJ Clements, PA Lachenbruch, SC Ng, et al. (1990) Skin score: a semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 33 1256-1263
18. D Khanna, RD Hays, P Maranian, et al. (2009) Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum 61 1257-1263
19. TA Medsger Jr, AJ Silman, VD Steen, et al. (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26 2159-2167
20. VD Steen and TA Medsger Jr (1997) The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 40 1984-1991
21. G Valentini, A Della Rossa, S Bombardieri, et al. (2001) European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 60 592-598
22. VD Steen, DL Powell and TA Medsger Jr (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31 196-203
23. EC LeRoy (1992) Raynaud's phenomenon, scleroderma, overlap syndromes, and other fibrosing syndromes. Curr Opin Rheumatol 4 821-824
24. HR Maricq and EC LeRoy (1973) Patterns of finger capillary abnormalities in connective tissue disease by “wide-field” microscopy. Arthritis Rheum 16 619-628
25. AL Herrick and M Cutolo (2010) Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum 62 2595-2604
26. M Cutolo, A Sulli, C Pizzorni, et al. (2000) Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 27 155-160
27. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon: results from a randomized clinical trial with 1-year follow-up. Arch Intern Med 160 1101-1108
28. A Kahan, B Amor and CJ Menkes (1985) A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon. Ann Rheum Dis 44 30-33
29. AE Thompson and JE Pope (2005) Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology (Oxford) 44 145-150
30. ME Anderson, TL Moore, S Hollis, et al. (2002) Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. Rheumatology 41 324-328
31. R Fries, K Shariat, H von Wilmowsky, et al. (2005) Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 112 2980-2985
32. J Gore and R Silver (2005) Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 64 1387
33. M Kuwana, J Kaburaki, Y Okazaki, et al. (2006) Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum 54 1946-1951
34. A Abou-Raya, S Abou-Raya and M Helmii (2008) Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol 35 1801-1808
35. MD Mayes (2003) Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 48 1190-1199
36. JH Korn, M Mayes, M Matucci Cerinic, et al. (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50 3985-3993
37. SV Kotsis and KC Chung (2003) A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia. J Rheumatol 30 1788-1792
38. JC Yarze, J Varga, D Stampfl, et al. (1993) Esophageal function in systemic sclerosis: a prospective evaluation of motility and acid reflux in 36 patients. Am J Gastroenterol 88 870-876
39. G Lock, RH Straub, M Zeuner, et al. (1998) Association of autonomic nervous dysfunction and esophageal dysmotility in systemic sclerosis. J Rheumatol 25 1330-1335
40. DP Tashkin, R Elashoff, PJ Clements, et al. (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354 2655-2666
41. D Bouros, AU Wells, AG Nicholson, et al. (2002) Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165 1581-1586
42. RB Christmann, AU Wells, VL Capelozzi, et al. (2010) Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum 40 241-249
43. JG Goldin, DA Lynch, DC Strollo, et al. (2008) High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 134 358-367
44. NS Goh, SR Desai, S Veeraraghavan, et al. (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177 1248-1254
45. RM Silver, JF Metcalf, JH Stanley, et al. (1984) Interstitial lung disease in scleroderma: analysis by bronchoalveolar lavage. Arthritis Rheum 27 1254-1262
46. RM Silver and AU Wells (2008) Histopathology and bronchoalveolar lavage. Rheumatology (Oxford) 47(Suppl 5), v62-v64
47. S Mittoo, FM Wigley, R Wise, et al. (2007) Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease. Arthritis Rheum 56 4195-4202
48. L Schachna, TA Medsger Jr, JH Dauber, et al. (2006) Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 54 3954-3961
49. VM Hsu, AE Moreyra, AC Wilson, et al. (2008) Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 35 458-465
50. V Steen and TA Medsger Jr (2003) Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 48 516-522
51. Y Allanore, D Borderie, J Avouac, et al. (2008) High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 58 284-291
52. E Hachulla, V Gressin, L Guillevin, et al. (2005) Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 52 3792-3800
53. MR Fisher, SC Mathai, HC Champion, et al. (2006) Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 54 3043-3050
54. SM Kawut, DB Taichman, CL Archer-Chicko, et al. (2003) Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 123 344-350
55. B Chang, FM Wigley, B White, et al. (2003) Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 30 2398-2405
56. SC Mathai, LK Hummers, HC Champion, et al. (2009) Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 60 569-577
57. MH Williams, CE Handler, R Akram, et al. (2006) Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 27 1485-1494
58. PR Forfia, MR Fisher, SC Mathai, et al. (2006) Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 174 1034-1041
59. A Campo, SC Mathai, J Le Pavec, et al. (2010) Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 182 252-260
60. MH Williams, C Das, CE Handler, et al. (2006) Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 92 926-932
61. MM Hoeper, C Faulenbach, H Golpon, et al. (2004) Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 24 1007-1010
62. JP Ioannidis, PG Vlachoyiannopoulos, AB Haidich, et al. (2005) Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 118 2-10
63. Y Allanore, C Meune and A Kahan (2008) Outcome measures for heart involvement in systemic sclerosis. Rheumatology 47(Suppl 5), v51-v53
64. RJ Byers, DA Marshall and AJ Freemont (1997) Pericardial involvement in systemic sclerosis. Ann Rheum Dis 56 393-394
65. TN James (1974) De subitaneis mortibus. VIII. Coronary arteries and conduction system in scleroderma heart disease. Circulation 50 844-856
66. EL Alexander, GS Firestein, JL Weiss, et al. (1986) Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. Ann Intern Med 105 661-668
67. A Kahan and Y Allanore (2006) Primary myocardial involvement in systemic sclerosis. Rheumatology (Oxford) 45(Suppl 4), iv14-iv17
68. C Meune, J Avouac, K Wahbi, et al. (2008) Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: a controlled study of 100 consecutive patients. Arthritis Rheum 58 1803-1809
69. A Fijalkowska, M Kurzyna, A Torbicki, et al. (2006) Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 129 1313-1321
70. VD Steen, A Syzd, JP Johnson, et al. (2005) Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol 32 649-655
71. H Penn, AJ Howie, EJ Kingdon, et al. (2007) Scleroderma renal crisis: patient characteristics and long-term outcomes. Q J Med 100 485-494
72. L Teixeira, L Mouthon, A Mahr, et al. (2008) Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 67 110-116
73. PJ Clements, PA Lachenbruch, DE Furst, et al. (1994) Abnormalities of renal physiology in systemic sclerosis: a prospective study with 10-year followup. Arthritis Rheum 37 67-74
74. VD Steen (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35 35-42
75. M Baron, P Lee and EC Keystone (1982) The articular manifestations of progressive systemic sclerosis (scleroderma). Ann Rheum Dis 41 147-152
76. J Avouac, U Walker, A Tyndall, et al. (2010) Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol 37 1488-1501
77. J Avouac, H Guerini, J Wipff, et al. (2006) Radiological hand involvement in systemic sclerosis. Ann Rheum Dis 65 1088-1092
78. G Szucs, Z Szekanecz, E Zilahi, et al. (2007) Systemic sclerosis-rheumatoid arthritis overlap syndrome: a unique combination of features suggests a distinct genetic, serological and clinical entity. Rheumatology (Oxford) 46 989-993
79. LE Kahl, TA Medsger Jr and I Klein (1986) Prospective evaluation of thyroid function in patients with systemic sclerosis (scleroderma). J Rheumatol 13 103-107
80. A Antonelli, C Ferri, P Fallahi, et al. (2007) Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis. Eur J Endocrinol 156 431-437
81. RK Hoyles, RW Ellis, J Wellsbury, et al. (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54 3962-3970
82. CT Derk, E Grace, M Shenin, et al. (2009) A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford) 48 1595-1599
83. SN Liossis, A Bounas and AP Andonopoulos (2006) Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 45 1005-1008
84. SI Nihtyanova, GM Brough, CM Black, et al. (2007) Mycophenolate mofetil in diffuse cutaneous systemic sclerosis—a retrospective analysis. Rheumatology (Oxford) 46 442-445
85. C Paone, I Chiarolanza, G Cuomo, et al. (2007) Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol 25 613-616
86. A Berezne, B Ranque, D Valeyre, et al. (2008) Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol 35 1064-1072
87. FH van den Hoogen, AM Boerbooms, AJ Swaak, et al. (1996) Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 35 364-372
88. JE Pope, N Bellamy, JR Seibold, et al. (2001) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44 1351-1358
89. PJ Clements, PA Lachenbruch, M Sterz, et al. (1993) Cyclosporine in systemic sclerosis: results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 36 75-83
90. RM Knobler, LE French, Y Kim, et al. (2006) A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis. J Am Acad Dermatol 54 793-799
91. V Smith, JT Van Praet, B Vandooren, et al. (2010) Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 69 193-197
92. R Lafyatis, E Kissin, M York, et al. (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60 578-583
93. M Binks, JR Passweg, D Furst, et al. (2001) Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 60 577-584
94. D Farge, J Passweg, JM van Laar, et al. (2004) Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 63 974-981
95. Y Oyama, WG Barr, L Statkute, et al. (2007) Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. Bone Marrow Transplant 40 549-555
96. CV Tehlirian, LK Hummers, B White, et al. (2008) High-dose cyclophosphamide without stem cell rescue in scleroderma. Ann Rheum Dis 67 775-781
97. CT Derk, G Huaman and SA Jimenez (2008) A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. Br J Dermatol 158 1063-1068
98. PJ Clements, DE Furst, WK Wong, et al. (1999) High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 42 1194-1203
99. CP Denton, PA Merkel, DE Furst, et al. (2007) Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 56 323-333
100. C Skhirtladze, O Distler, C Dees, et al. (2008) Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum 58 1475-1484
101. M Pines, D Snyder, S Yarkoni, et al. (2003) Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant 9 417-425
102. M Wu, DS Melichian, E Chang, et al. (2009) Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol 174 519-533
103. RM Laxer and F Zulian (2006) Localized scleroderma. Curr Opin Rheumatol 18 606-613
104. F Boin and LK Hummers (2008) Scleroderma-like fibrosing disorders. Rheum Dis Clin North Am 34 199-220
105. S Lakhanpal, WW Ginsburg, CJ Michet, et al. (1988) Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum 17 221-231
106. M Blum, FM Wigley and LK Hummers (2008) Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine 87 10-20
107. A Kribben, O Witzke, U Hillen, et al. (2009) Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J Am Coll Cardiol 53 1621-1628
108. O Nadashkevich, P Davis, M Fritzler, et al. (2006) A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 25 205-212
109. DP Tashkin, R Elashoff, PJ Clements, et al. (2007) Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176 1026-1034
110. AJ Gerbino, CH Goss and JA Molitor (2008) Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 133 455-460
111. AC Zamora, PJ Wolters, HR Collard, et al. (2008) Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 102 150-155
112. C Paone, I Chiarolanza, G Cuomo, et al. (2007) Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol 25 613-616
113. RJ Stratton, H Wilson and CM Black (2001) Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 40 84-88
114. TI Su, D Khanna, DE Furst, et al. (2009) Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. Arthritis Rheum 60 3821-3830
115. D Daoussis, SN Liossis, AC Tsamandas, et al. (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 49 271-280
116. Y Levy, H Amital, P Langevitz, et al. (2004) Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum 50 1005-1007
117. F Nacci, A Righi, ML Conforti, et al. (2007) Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann Rheum Dis 66 977-979
118. GK Lam, LK Hummers, A Woods, et al. (2007) Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 34 1636-1637
119. CP Denton, M Engelhart, N Tvede, et al. (2009) An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 68 1433-1439
120. PA McSweeney, RA Nash, KM Sullivan, et al. (2002) High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 100 1602-1610
121. RA Nash, PA McSweeney, LJ Crofford, et al. (2007) High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 110 1388-1396
122. GP Rodnan and TG Benedek (1962) An historical account of the study of progressive systemic sclerosis (diffuse scleroderma). Ann Intern Med 57 305-319
123. AJ Barnett (1996) History of scleroderma. PJ Clements, DE Furst,(Eds) Systemic sclerosis Baltimore: Williams & Wilkins 3-22. 1996
124. W Osler (1894) The principles and practice of medicine. New York: Appleton p 993
125. R Goetz (1945) Pathology of progressive systemic sclerosis (generalized scleroderma) with special reference to changes in the viscera. Clin Proc S Africa 4 337-342
126. RH Winterbauer (1964) Multiple telangiectasia, Raynaud's phenomenon, sclerodactyly, and subcutaneous calcinosis: a syndrome mimicking hereditary hemorrhagic telangiectasia. Bull Johns Hopkins Hosp 114 361-383
127. EE Velayos, AT Masi, MB Stevens, et al. (1979) The ‘CREST’ syndrome: comparison with systemic sclerosis (scleroderma). Arch Intern Med 139 1240-1244
128. WA D’Angelo, JF Fries, AT Masi, et al. (1969) Pathologic observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 46 428-440
129. GP Rodnan, E Lipinski and J Luksick (1979) Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 22 130-140
130. MD Mayes, JVJ Lacey, J Beebe-Dimmer, et al. (2003) Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48 2246-2255
131. T Tamaki, S Mori and K Takehara (1991) Epidemiological study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res 283 366-371
132. FC Arnett, RF Howard, F Tan, et al. (1996) Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma: association with an Amerindian HLA haplotype. Arthritis Rheum 39 1362-1370
133. PJ Nietert, HC Mitchell, MB Bolster, et al. (2006) Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol 33 263-268
134. G Valesini, A Litta, MS Bonavita, et al. (1993) Geographical clustering of scleroderma in a rural area in the province of Rome. Clin Exp Rheumatol 11 41-47
135. AJ Silman, Y Howard, AJ Hicklin, et al. (1990) Geographical clustering of scleroderma in south and west London. Br J Rheumatol 29 93-96
136. VD Steen, CV Oddis, CG Conte, et al. (1997) Incidence of systemic sclerosis in Allegheny County, Pennsylvania: a twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum 40 441-445
137. AJ Tyndall, B Bannert, M Vonk, et al. (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69 1809-1815
138. VD Steen and TA Medsger Jr (2000) Long-term outcomes of scleroderma renal crisis. Ann Intern Med 133 600-603
139. VD Steen and TA Medsger (2007) Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66 940-954
140. SI Nihtyanova, EC Tang, JG Coghlan, et al. (2010) Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. Q J Med 103 109-115
141. ZD McCormic, SS Khuder, BK Aryal, et al. (2010) Occupational silica exposure as a risk factor for scleroderma: a meta-analysis. Int Arch Occup Environ Health 83 763-769
142. FC Arnett, M Cho, S Chatterjee, et al. (2001) Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 44 1359-1362
143. C Feghali-Bostwick, TA Medsger Jr and TM Wright (2003) Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 48 1956-1963
144. JD Reveille, E Durban, MJ MacLeod-St Clair, et al. (1992) Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest 90 973-980
145. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23 581-590
146. CG Kallenberg, AA Wouda, MH Hoet, et al. (1988) Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 47 634-641
147. EC LeRoy and TA Medsger Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28 1573-1576
148. AJ Barnett, M Miller and GO Littlejohn (1988) The diagnosis and classification of scleroderma (systemic sclerosis). Postgrad Med J 64 121-125
149. PJ Clements, PA Lachenbruch, SC Ng, et al. (1990) Skin score: a semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 33 1256-1263
150. H Gazi, JE Pope, P Clements, et al. (2007) Outcome measurements in scleroderma: results from a Delphi exercise. J Rheumatol 34 501-509
151. PA Merkel, NP Silliman, CP Denton, et al. (2008) Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. Arthritis Rheum 59 699-705
152. D Khanna, RD Hays, P Maranian, et al. (2009) Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum 61 1257-1263
153. TA Medsger Jr, AJ Silman, VD Steen, et al. (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26 2159-2167
154. TA Medsger Jr, S Bombardieri, L Czirjak, et al. (2003) Assessment of disease severity and prognosis. Clin Exp Rheumatol 21(3 Suppl 29), S42-S46
155. VD Steen and TA Medsger Jr (1997) The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 40 1984-1991
156. PA Merkel, PJ Clements, JD Reveille, et al. (2003) Current status of outcome measure development for clinical trials in systemic sclerosis: report from OMERACT 6. J Rheumatol 30 1630-1647
157. G Valentini, A Della Rossa, S Bombardieri, et al. (2001) European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 60 592-598
158. VD Steen, DL Powell and TA Medsger Jr (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31 196-203
159. EC LeRoy (1992) Raynaud's phenomenon, scleroderma, overlap syndromes, and other fibrosing syndromes. Curr Opin Rheumatol 4 821-824
160. HR Maricq and EC LeRoy (1973) Patterns of finger capillary abnormalities in connective tissue disease by “wide-field” microscopy. Arthritis Rheum 16 619-628
161. ME Anderson, PD Allen, T Moore, et al. (2005) Computerized nailfold video capillaroscopy—a new tool for assessment of Raynaud's phenomenon. J Rheumatol 32 841-848
162. AL Herrick and M Cutolo (2010) Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum 62 2595-2604
163. M Cutolo, A Sulli, C Pizzorni, et al. (2000) Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 27 155-160
164. MK Karavidas, PS Tsai, C Yucha, et al. (2006) Thermal biofeedback for primary Raynaud's phenomenon: a review of the literature. Appl Psychophysiol Biofeedback 31 203-216
165. Y Allanore, D Borderie, H Lemarechal, et al. (2004) Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1. Arthritis Res Ther 6 R309-R314
166. R Malamet, RA Wise, WH Ettinger, et al. (1985) Nifedipine in the treatment of Raynaud's phenomenon: evidence for inhibition of platelet activation. Am J Med 78 602-608
167. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon: results from a randomized clinical trial with 1-year follow-up. Arch Intern Med 160 1101-1108
168. A Kahan, B Amor and CJ Menkes (1985) A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon. Ann Rheum Dis 44 30-33
169. AE Thompson and JE Pope (2005) Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology (Oxford) 44 145-150
170. ME Anderson, TL Moore, S Hollis, et al. (2002) Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. Rheumatology 41 324-328
171. C Kan, S Akimoto, M Abe, et al. (2002) Preliminary thermographic evaluation of new nitroglycerine tape on the peripheral circulatory disturbance in systemic sclerosis. Ann Rheum Dis 61 177-179
172. R Fries, K Shariat, H von Wilmowsky, et al. (2005) Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 112 2980-2985
173. J Gore and R Silver (2005) Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 64 1387
174. AE Gliddon, CJ Dore, CM Black, et al. (2007) Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 56 3837-3846
175. J Davignon (2004) Beneficial cardiovascular pleiotropic effects of statins. Circulation 109(23 Suppl 1), III39-III43
176. CP Sparrow, CA Burton, M Hernandez, et al. (2001) Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 21 115-121
177. CT Derk and SA Jimenez (2006) Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents? Autoimmun Rev 5 25-32
178. M Kuwana, J Kaburaki, Y Okazaki, et al. (2006) Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum 54 1946-1951
179. A Abou-Raya, S Abou-Raya and M Helmii (2008) Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol 35 1801-1808
180. MD Mayes (2003) Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 48 1190-1199
181. JH Korn, M Mayes, M Matucci Cerinic, et al. (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50 3985-3993
182. ER Bogoch and DK Gross (2005) Surgery of the hand in patients with systemic sclerosis: outcomes and considerations. J Rheumatol 32 642-648
183. SV Kotsis and KC Chung (2003) A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia. J Rheumatol 30 1788-1792
184. JH Park, YK Sung, SC Bae, et al. (2009) Ulnar artery vasculopathy in systemic sclerosis. Rheumatol Int 29 1081-1086
185. JC Yarze, J Varga, D Stampfl, et al. (1993) Esophageal function in systemic sclerosis: a prospective evaluation of motility and acid reflux in 36 patients. Am J Gastroenterol 88 870-876
186. G Lock, RH Straub, M Zeuner, et al. (1998) Association of autonomic nervous dysfunction and esophageal dysmotility in systemic sclerosis. J Rheumatol 25 1330-1335
187. DP Tashkin, R Elashoff, PJ Clements, et al. (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354 2655-2666
188. D Bouros, AU Wells, AG Nicholson, et al. (2002) Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165 1581-1586
189. RB Christmann, AU Wells, VL Capelozzi, et al. (2010) Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum 40 241-249
190. JG Goldin, DA Lynch, DC Strollo, et al. (2008) High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 134 358-367
191. NS Goh, SR Desai, S Veeraraghavan, et al. (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177 1248-1254
192. RM Silver, JF Metcalf, JH Stanley, et al. (1984) Interstitial lung disease in scleroderma: analysis by bronchoalveolar lavage. Arthritis Rheum 27 1254-1262
193. RM Silver and AU Wells (2008) Histopathology and bronchoalveolar lavage. Rheumatology (Oxford) 47(Suppl 5), v62-v64
194. S Mittoo, FM Wigley, R Wise, et al. (2007) Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease. Arthritis Rheum 56 4195-4202
195. L Schachna, TA Medsger Jr, JH Dauber, et al. (2006) Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 54 3954-3961
196. VM Hsu, AE Moreyra, AC Wilson, et al. (2008) Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 35 458-465
197. V Steen and TA Medsger Jr (2003) Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 48 516-522
198. Y Allanore, D Borderie, J Avouac, et al. (2008) High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 58 284-291
199. D Mukerjee, D St George, B Coleiro, et al. (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62 1088-1093
200. E Hachulla, V Gressin, L Guillevin, et al. (2005) Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 52 3792-3800
201. MR Fisher, SC Mathai, HC Champion, et al. (2006) Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 54 3043-3050
202. SM Kawut, DB Taichman, CL Archer-Chicko, et al. (2003) Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 123 344-350
203. B Chang, FM Wigley, B White, et al. (2003) Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 30 2398-2405
204. SC Mathai, LK Hummers, HC Champion, et al. (2009) Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 60 569-577
205. MH Williams, CE Handler, R Akram, et al. (2006) Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 27 1485-1494
206. SC Mathai, M Bueso, LK Hummers, et al. (2010) Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J 35 95-104
207. PR Forfia, MR Fisher, SC Mathai, et al. (2006) Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 174 1034-1041
208. A Campo, SC Mathai, J Le Pavec, et al. (2010) Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 182 252-260
209. MH Williams, C Das, CE Handler, et al. (2006) Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 92 926-932
210. MM Hoeper, C Faulenbach, H Golpon, et al. (2004) Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 24 1007-1010
211. SC Mathai, RE Girgis, MR Fisher, et al. (2007) Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 29 469-475
212. PJ Clements, PA Lachenbruch, DE Furst, et al. (1991) Cardiac score: a semiquantitative measure of cardiac involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 34 1371-1380
213. JP Ioannidis, PG Vlachoyiannopoulos, AB Haidich, et al. (2005) Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 118 2-10
214. Y Allanore, C Meune, MC Vonk, et al. (2010) Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 69 218-221
215. Y Allanore, C Meune and A Kahan (2008) Outcome measures for heart involvement in systemic sclerosis. Rheumatology (Oxford) 47(Suppl 5), v51-v53
216. RJ Byers, DA Marshall and AJ Freemont (1997) Pericardial involvement in systemic sclerosis. Ann Rheum Dis 56 393-394
217. MR Akram, CE Handler, M Williams, et al. (2006) Angiographically proven coronary artery disease in scleroderma. Rheumatology (Oxford) 45 1395-1398
218. TN James (1974) De subitaneis mortibus. VIII. Coronary arteries and conduction system in scleroderma heart disease. Circulation 50 844-856
219. R Montisci, A Vacca, P Garau, et al. (2003) Detection of early impairment of coronary flow reserve in patients with systemic sclerosis. Ann Rheum Dis 62 890-893
220. EL Alexander, GS Firestein, JL Weiss, et al. (1986) Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. Ann Intern Med 105 661-668
221. A Nitenberg, JM Foult, A Kahan, et al. (1986) Reduced coronary flow and resistance reserve in primary scleroderma myocardial disease. Am Heart J 112 309-315
222. A Kahan and Y Allanore (2006) Primary myocardial involvement in systemic sclerosis. Rheumatology (Oxford) 45(Suppl 4), iv14-iv17
223. C Meune, J Avouac, K Wahbi, et al. (2008) Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: a controlled study of 100 consecutive patients. Arthritis Rheum 58 1803-1809
224. AL Hachulla, D Launay, V Gaxotte, et al. (2009) Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 68 1878-1884
225. A Fijalkowska, M Kurzyna, A Torbicki, et al. (2006) Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 129 1313-1321
226. A Scheja, I Bartosik, DM Wuttge, et al. (2009) Renal function is mostly preserved in patients with systemic sclerosis. Scand J Rheumatol 38 295-298
227. VD Steen, A Syzd, JP Johnson, et al. (2005) Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol 32 649-655
228. DL Kamen, FM Wigley and AN Brown (2006) Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis in scleroderma—a different kind of renal crisis. J Rheumatol 33 1886-1888
229. H Penn, AJ Howie, EJ Kingdon, et al. (2007) Scleroderma renal crisis: patient characteristics and long-term outcomes. Q J Med 100 485-494
230. L Teixeira, L Mouthon, A Mahr, et al. (2008) Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 67 110-116
231. PJ Clements, PA Lachenbruch, DE Furst, et al. (1994) Abnormalities of renal physiology in systemic sclerosis: a prospective study with 10-year followup. Arthritis Rheum 37 67-74
232. VD Steen (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35 35-42
233. GP Rodnan and TA Medsger (1968) The rheumatic manifestations of progressive systemic sclerosis (scleroderma). Clin Orthop Relat Res 57 81-93
234. M Baron, P Lee and EC Keystone (1982) The articular manifestations of progressive systemic sclerosis (scleroderma). Ann Rheum Dis 41 147-152
235. J Avouac, U Walker, A Tyndall, et al. (2010) Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol 37 1488-1501
236. G Cuomo, M Zappia, G Abignano, et al. (2009) Ultrasonographic features of the hand and wrist in systemic sclerosis. Rheumatology (Oxford) 48 1414-1417
237. AH Low, M Lax, SR Johnson, et al. (2009) Magnetic resonance imaging of the hand in systemic sclerosis. J Rheumatol 36 961-964
238. J Avouac, H Guerini, J Wipff, et al. (2006) Radiological hand involvement in systemic sclerosis. Ann Rheum Dis 65 1088-1092
239. G Szucs, Z Szekanecz, E Zilahi, et al. (2007) Systemic sclerosis-rheumatoid arthritis overlap syndrome: a unique combination of features suggests a distinct genetic, serological and clinical entity. Rheumatology (Oxford) 46 989-993
240. M Jinnin, H Ihn, K Yamane, et al. (2003) Clinical features of patients with systemic sclerosis accompanied by rheumatoid arthritis. Clin Exp Rheumatol 21 91-94
241. WP Follansbee, TR Zerbe and TA Medsger Jr (1993) Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J 125 194-203
242. MB Gordon, I Klein, A Dekker, et al. (1981) Thyroid disease in progressive systemic sclerosis: increased frequency of glandular fibrosis and hypothyroidism. Ann Intern Med 95 431-435
243. LE Kahl, TA Medsger Jr and I Klein (1986) Prospective evaluation of thyroid function in patients with systemic sclerosis (scleroderma). J Rheumatol 13 103-107
244. A Antonelli, C Ferri, P Fallahi, et al. (2007) Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis. Eur J Endocrinol 156 431-437
245. E Biro, Z Szekanecz, L Czirjak, et al. (2006) Association of systemic and thyroid autoimmune diseases. Clin Rheumatol 25 240-245
246. M Hudson, A Rojas-Villarraga, P Coral-Alvarado, et al. (2008) Polyautoimmunity and familial autoimmunity in systemic sclerosis. J Autoimmun 31 156-159
247. RK Hoyles, RW Ellis, J Wellsbury, et al. (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54 3962-3970
248. CT Derk, E Grace, M Shenin, et al. (2009) A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford) 48 1595-1599
249. SN Liossis, A Bounas and AP Andonopoulos (2006) Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 45 1005-1008
250. SI Nihtyanova, GM Brough, CM Black, et al. (2007) Mycophenolate mofetil in diffuse cutaneous systemic sclerosis—a retrospective analysis. Rheumatology (Oxford) 46 442-445
251. C Paone, I Chiarolanza, G Cuomo, et al. (2007) Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol 25 613-616
252. K Dheda, UG Lalloo, B Cassim, et al. (2004) Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 23 306-309
253. A Berezne, B Ranque, D Valeyre, et al. (2008) Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol 35 1064-1072
254. FH van den Hoogen, AM Boerbooms, AJ Swaak, et al. (1996) Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 35 364-372
255. JE Pope, N Bellamy, JR Seibold, et al. (2001) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44 1351-1358
256. SJ Morton and RJ Powell (2000) Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma. Rheumatology 39 865-869
257. PJ Clements, PA Lachenbruch, M Sterz, et al. (1993) Cyclosporine in systemic sclerosis: results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 36 75-83
258. RM Knobler, LE French, Y Kim, et al. (2006) A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis. J Am Acad Dermatol 54 793-799
259. V Smith, JT Van Praet, B Vandooren, et al. (2010) Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 69 193-197
260. R Lafyatis, E Kissin, M York, et al. (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60 578-583
261. M Binks, JR Passweg, D Furst, et al. (2001) Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 60 577-584
262. D Farge, J Passweg, JM van Laar, et al. (2004) Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 63 974-981
263. Y Oyama, WG Barr, L Statkute, et al. (2007) Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. Bone Marrow Transplant 40 549-555
264. CV Tehlirian, LK Hummers, B White, et al. (2008) High-dose cyclophosphamide without stem cell rescue in scleroderma. Ann Rheum Dis 67 775-781
265. CT Derk, G Huaman and SA Jimenez (2008) A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. Br J Dermatol 158 1063-1068
266. PJ Clements, DE Furst, WK Wong, et al. (1999) High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 42 1194-1203
267. CP Denton, PA Merkel, DE Furst, et al. (2007) Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 56 323-333
268. C Skhirtladze, O Distler, C Dees, et al. (2008) Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum 58 1475-1484
269. M Pines, D Snyder, S Yarkoni, et al. (2003) Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant 9 417-425
270. M Wu, DS Melichian, E Chang, et al. (2009) Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol 174 519-533
271. P Spagnolo, C Del Giovane, F Luppi, et al. (2010) Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 9 CD003134
272. Y Ikawa, PS Ng, K Endo, et al. (2008) Neutralizing monoclonal antibody to human connective tissue growth factor ameliorates transforming growth factor-beta-induced mouse fibrosis. J Cell Physiol 216 680-687
273. RM Laxer and F Zulian (2006) Localized scleroderma. Curr Opin Rheumatol 18 606-613
274. F Boin and LK Hummers (2008) Scleroderma-like fibrosing disorders. Rheum Dis Clin North Am 34 199-220
275. S Lakhanpal, WW Ginsburg, CJ Michet, et al. (1988) Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum 17 221-231
276. M Blum, FM Wigley and LK Hummers (2008) Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine 87 10-20
277. A Kribben, O Witzke, U Hillen, et al. (2009) Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J Am Coll Cardiol 53 1621-1628
278. O Nadashkevich, P Davis, M Fritzler, et al. (2006) A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 25 205-212
279. DP Tashkin, R Elashoff, PJ Clements, et al. (2007) Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176 1026-1034
280. AJ Gerbino, CH Goss and JA Molitor (2008) Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 133 455-460
281. AC Zamora, PJ Wolters, HR Collard, et al. (2008) Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 102 150-155
282. K Dheda, UG Lalloo, B Cassim, et al. (2004) Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 23 306-309
283. C Paone, I Chiarolanza, G Cuomo, et al. (2007) Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol 25 613-616
284. G Filaci, M Cutolo, M Scudeletti, et al. (1999) Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology (Oxford) 38 992-996
285. EL Matteson, MI Shbeeb, TG McCarthy, et al. (1996) Pilot study of antithymocyte globulin in systemic sclerosis. Arthritis Rheum 39 1132-1137
286. RJ Stratton, H Wilson and CM Black (2001) Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 40 84-88
287. AH Rook, B Freundlich and BV Jegasothy (1993) Photopheresis for scleroderma? Let's abandon the innuendos and get to the data. J Rheumatol 20 1081-1083
288. K Krasagakis, E Dippel, J Ramaker, et al. (1998) Management of severe scleroderma with long-term extracorporeal photopheresis. Dermatology 196 309-315
289. TI Su, D Khanna, DE Furst, et al. (2009) Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. Arthritis Rheum 60 3821-3830
290. D Daoussis, SN Liossis, AC Tsamandas, et al. (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 49 271-280
291. Y Levy, Y Sherer, P Langevitz, et al. (2000) Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin—a preliminary report. Clin Rheumatol 19 207-211
292. H Amital, E Rewald, Y Levy, et al. (2003) Fibrosis regression induced by intravenous gammaglobulin treatment. Ann Rheum Dis 62 175-177
293. Y Levy, H Amital, P Langevitz, et al. (2004) Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum 50 1005-1007
294. H Ihn, Y Mimura, N Yazawa, et al. (2007) High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma. Br J Dermatol 156 1058-1060
295. F Nacci, A Righi, ML Conforti, et al. (2007) Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann Rheum Dis 66 977-979
296. GK Lam, LK Hummers, A Woods, et al. (2007) Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 34 1636-1637
297. CP Denton, M Engelhart, N Tvede, et al. (2009) An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 68 1433-1439
298. J Gordon, J Mersten, S Lyman, et al. (2009) Imatinib mesylate (Gleevec) in the treatment of systemic sclerosis: interim results of a phase IIa, one year, open label clinical trial. Arthritis Rheum 60(Suppl 10), 414
299. J Pope, DL McBain, L Petrlich, et al. (2009) A proof of concept trial of Gleevec (imatinib) in active diffuse scleroderma (DSSc). Arthritis Rheum 60(Suppl 10), 608
300. PA McSweeney, RA Nash, KM Sullivan, et al. (2002) High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 100 1602-1610
301. RA Nash, PA McSweeney, LJ Crofford, et al. (2007) High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 110 1388-1396